Results

Wegovy First Month: What to Expect Week by Week

GLP-1 Companion · 7 min read

Wegovy (semaglutide 2.4mg) is the highest-dose semaglutide formulation, approved specifically for chronic weight management in adults with obesity or overweight with a weight-related comorbidity. Despite its eventual potency, the first month is deliberately slow — a structured adaptation period designed to maximize tolerability. Here is what each week of that first month actually looks like.

Wegovy's Titration Schedule: Why Month 1 Stays at 0.25mg

Wegovy uses a five-step titration over 16 weeks to reach its target dose of 2.4mg. The first four weeks use 0.25mg — the same initiation dose as Ozempic. At week 5, the dose increases to 0.5mg. The subsequent escalations occur at four-week intervals: 1mg at week 9, 1.7mg at week 13, and the maintenance dose of 2.4mg at week 17. The entire first month, therefore, occurs at the lowest possible dose.

1. Weeks 1–4: 0.25mg — initiation and tolerability phase.
2. Weeks 5–8: 0.5mg — first therapeutic escalation.
3. Weeks 9–12: 1mg — intermediate therapeutic dose.
4. Weeks 13–16: 1.7mg — near-maintenance dose.
5. Week 17 onward: 2.4mg — full maintenance dose.

Week 1: The First Injection

Most patients tolerate the first Wegovy injection without dramatic symptoms. Because the starting dose is very low, the GLP-1 receptor activation is gentle. You may notice a modest reduction in appetite within a few days. Nausea, if present at all, is usually mild. Some patients feel slightly fatigued or notice looser stools as their gastrointestinal system begins adapting to slowed gastric motility.

Week 2: Nausea Peak and Early Appetite Changes

Week two is typically when nausea, if it is going to occur, reaches its peak. This corresponds to semaglutide reaching approximate steady-state plasma levels after the second injection. Most patients who experience nausea describe it as mild to moderate — an underlying queasiness rather than vomiting — that is worse in the hours after eating, particularly after large or fatty meals. Food noise often starts diminishing noticeably during this week for many patients.

• Nausea most commonly occurs 30–60 minutes after meals and resolves within a few hours.
• Smaller, lower-fat meals dramatically reduce nausea intensity.
• Eating slowly and stopping before feeling full helps avoid triggering nausea.
• Staying upright for 30–60 minutes after eating reduces discomfort.

Week 3: Adaptation Begins

By week three, many patients report that nausea has begun to ease compared to week two. The body is adapting to altered gastric motility and the hormonal effects of semaglutide. Appetite suppression may feel more consistent and less variable. Some patients notice clearer changes in how they relate to food — less urgency around meals, reduced cravings, and a general sense that food has become less emotionally significant.

Week 4: End of Month 1

By the end of week four, most patients have adapted reasonably well to the 0.25mg dose. The scale may show modest movement — typically 1–3% of starting body weight, corresponding to roughly 2–6 pounds for someone starting at 200 pounds. Some patients see no scale change but report that their clothes fit differently, suggesting body composition changes even before the number moves. Others are slightly frustrated that results feel slow, which is a completely normal and expected experience at this dose.

Clinical data consistently shows that meaningful weight loss on Wegovy begins to accelerate from months 2 through 4, as the dose escalates. The first month sets the stage; it is not the main act.

Average Weight Loss by End of Month 1

Real-world experience and sub-analyses of the STEP trials suggest that average weight loss by the end of week four on semaglutide is approximately 1–3% of starting body weight. For reference, a 230-pound person might lose 2–7 pounds in the first month. The STEP 1 trial, which enrolled adults without diabetes, showed that the majority of the 15.3% average total weight loss accumulated after month two, with the first month representing a disproportionately small fraction of the total outcome.

What the STEP Trials Say About Early Outcomes

The STEP (Semaglutide Treatment Effect in People with Obesity) trial program is the most comprehensive clinical evidence base for Wegovy. STEP 1 enrolled 1,961 adults with obesity or overweight with comorbidities. The weight loss curve shows a characteristic shape: relatively gradual in weeks 1–8, then steepening noticeably from months 3 through 9, followed by a plateau phase. This means most of the dramatic weight loss in the STEP trials occurred well after the first month.

• STEP 1 (68 weeks): Average 15.3% weight loss from baseline in the semaglutide group.
• The steepest weight loss occurred between approximately months 2 and 9.
• By week 12 (end of month 3), average losses were already meaningful at approximately 7–8% in some analyses.
• By week 20 (end of month 5), many participants had achieved 10% or more weight loss.

Early Signs That Wegovy Is Working

Looking beyond the scale in month one reveals more meaningful early indicators that Wegovy is doing what it is supposed to do. These subjective signals are clinically relevant because they reflect the neurological and hormonal changes that drive eventual weight loss.

• Reduced food noise: Thoughts about food feel less intrusive and compulsive.
• Smaller appetite: Meals feel complete at smaller portions without conscious restriction.
• Reduced cravings: Particularly for high-fat, high-sugar foods — a well-documented GLP-1 effect.
• Changed food preferences: Some patients spontaneously gravitate toward less palatable but healthier foods.
• Reduced alcohol desire: Many patients drink less without trying — a recognized semaglutide effect.

Managing Expectations and Staying the Course

The most important factor in Wegovy outcomes is continuation. Data shows that patients who discontinue during the first three months — often during the adaptation phase before full therapeutic doses are reached — miss the bulk of the medication's benefit. Healthcare providers consistently report that the patients who see the most dramatic results are those who push through the modest first month and allow the titration schedule to work as designed.

Sources

• Wilding et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM.
• Wegovy (semaglutide) Prescribing Information. Novo Nordisk.